Stock HIKAL HIKAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hikal Limited

Equities

HIKAL

INE475B01022

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:49 2024-04-26 am EDT 		5-day change 1st Jan Change
312.3 INR +1.17% Intraday chart for Hikal Limited +4.55% +2.90%
Apr. 08 Hikal Limited agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million. CI
Apr. 01 Hikal Limited Announces Completion of Tenure of Non-Executive, Independent Directors CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 21,571 8,631 17,694 49,622 34,758 38,507 - -
Enterprise Value (EV) 1 21,571 8,631 17,694 49,622 34,758 38,507 38,507 38,507
P/E ratio 20.9 x 10.2 x 13.3 x 30.9 x 44.3 x 56.8 x 37.2 x 25.2 x
Yield 0.69% 1.71% 1.39% 0.4% 0.43% 0.19% 0.19% 0.19%
Capitalization / Revenue 1.36 x 0.57 x 1.03 x 2.55 x 1.72 x 2.13 x 1.85 x 1.61 x
EV / Revenue 1.36 x 0.57 x 1.03 x 2.55 x 1.72 x 2.13 x 1.85 x 1.61 x
EV / EBITDA 7.24 x 3.16 x 5.48 x 14.6 x 13.5 x 14.9 x 12.2 x 9.71 x
EV / FCF 37,738,084 x 6,801,460 x 24,770,625 x 243,008,750 x 273,904,503 x - - -
FCF Yield 0% 0% 0% 0% 0% - - -
Price to Book 2.85 x 1.06 x 1.9 x 4.65 x 3.07 x 3.22 x 2.99 x 2.68 x
Nbr of stocks (in thousands) 123,301 123,301 123,301 123,301 123,301 123,301 - -
Reference price 2 175.0 70.00 143.5 402.4 281.9 312.3 312.3 312.3
Announcement Date 5/9/19 6/18/20 5/6/21 5/28/22 5/29/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 15,896 15,073 17,204 19,427 20,230 18,077 20,780 23,971
EBITDA 1 2,981 2,732 3,229 3,406 2,571 2,587 3,169 3,967
EBIT 1 2,052 - 2,376 2,449 - 1,477 1,941 2,617
Operating Margin 12.91% - 13.81% 12.61% - 8.17% 9.34% 10.92%
Earnings before Tax (EBT) 1 1,491 1,266 2,064 2,186 1,054 917 1,375 2,031
Net income 1 1,031 844.3 1,332 1,605 783.9 682 1,031 1,523
Net margin 6.48% 5.6% 7.74% 8.26% 3.87% 3.77% 4.96% 6.35%
EPS 2 8.360 6.850 10.80 13.02 6.360 5.500 8.400 12.40
Free Cash Flow 571.6 1,269 714.3 204.2 126.9 - - -
FCF margin 3.6% 8.42% 4.15% 1.05% 0.63% - - -
FCF Conversion (EBITDA) 19.17% 46.46% 22.12% 6% 4.94% - - -
FCF Conversion (Net income) 55.46% 150.3% 53.65% 12.72% 16.19% - - -
Dividend per Share 2 1.200 1.200 2.000 1.600 1.200 0.6000 0.6000 0.6000
Announcement Date 5/9/19 6/18/20 5/6/21 5/28/22 5/29/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 3,788 5,588 5,384 5,379 3,861 4,716 5,112 5,459
EBITDA 1 227.5 697.3 745.8 880.1 502.9 727 762 844
EBIT - - - - - - - -
Operating Margin - - - - - - - -
Earnings before Tax (EBT) - - - - - - - -
Net income 1 -88.6 248.4 264.1 360 69.2 245 278 366
Net margin -2.34% 4.45% 4.9% 6.69% 1.79% 5.2% 5.44% 6.7%
EPS - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 8/10/22 11/9/22 2/2/23 5/29/23 8/8/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 572 1,269 714 204 127 - - -
ROE (net income / shareholders' equity) 14.5% 12% 15.2% 16% 7.12% 5.9% 8.3% 11.2%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 61.30 66.20 75.70 86.60 91.90 96.90 105.0 116.0
Cash Flow per Share - - - - - - - -
Capex 1,284 1,580 1,576 2,733 3,026 - 1,485 1,487
Capex / Sales 8.08% 10.48% 9.16% 14.07% 14.96% - 7.15% 6.2%
Announcement Date 5/9/19 6/18/20 5/6/21 5/28/22 5/29/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hikal Limited

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
312.3 INR
Average target price
330 INR
Spread / Average Target
+5.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HIKAL LIMITED Stock Hikal Limited
+2.90% 462M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HIKAL Stock
  4. Financials Hikal Limited